TNFRSF1B and familial pancreatic carcinoma: The anti-TNFR1 antibodies did not affect the level of the PD-L1 protein in TNF-α-treated KPC cells, whereas the addition of anti-TNFR2 antibodies abolished the TNF-α-induced upregulation of PD-L1 expression in pancreatic cancer cells (figure 4B).